Cargando…
Liposomal formulation of Gp41 derivate with adjuvant MPLA: vaccine design, immunogenicity in animals and safety in humans
Autores principales: | Katinger, D, Wagner, A, Luque, I, Crespillo, S, Conejero-Lara, F, Roger, M, Martin, C, Mouz, N, Mourao, S, Farsang, A, Notka, F, Malcolm, K, Bosquet, N, Le Grand, R, Moog, C, Cope, A, Shattock, R, Lewis, DJ, El Habib, R |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3441855/ http://dx.doi.org/10.1186/1742-4690-9-S2-P354 |
Ejemplares similares
-
Sublingual Priming with a HIV gp41-Based Subunit Vaccine Elicits Mucosal Antibodies and Persistent B Memory Responses in Non-Human Primates
por: Bekri, Selma, et al.
Publicado: (2017) -
P14-06. Phase 1 safety and immunogenicity randomised controlled trial of a vaginal gp140 vaccine
por: Lewis, DJ, et al.
Publicado: (2009) -
CN54gp140: product characteristics, peclinical and clinical use - recombinant glycoprotein for HIV immunization
por: Katinger, D, et al.
Publicado: (2012) -
Conformational Stabilization of Gp41-Mimetic Miniproteins Opens Up New Ways of Inhibiting HIV-1 Fusion
por: Cano-Muñoz, Mario, et al.
Publicado: (2022) -
P19-02. High protection of female macaques from repeated intravaginal challenges with SHIV-162P3 upon mucosal vaccination with Gp41 subunits-virosomes
por: Bomsel, M, et al.
Publicado: (2009)